<DOC>
	<DOC>NCT01356914</DOC>
	<brief_summary>The purpose of the study is to determine whether treatment with BMS-914392 is safe, well tolerated and associated with a reduction of atrial fibrillation burden in patients with paroxysmal atrial fibrillation and permanent pacemaker.</brief_summary>
	<brief_title>Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Paroxysmal atrial fibrillation (AF) Programmable dual chamber pacemaker with appropriate arrhythmia diagnostics. 150% AF burden on pacemaker interrogation at screening. Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy. Persistent or permanent AF. AF Burden &lt;1% or &gt; 50%. Current or history of neurological diseases and mental disorders. Ejection Fraction &lt; 45%. Severe mitral or aortic valve dysfunction. TIA (Transient Ischemic Attack) within last 12 months. Acute coronary syndrome in the last 2 months. Previous AF ablation. Cardioversion in last 3 months. Current kidney or liver disease, or current cancer. History of neurological and mental disorders. Major surgery within 4 weeks of first dose (cardiac surgery within 4 months). Screening lab test results outside of allowed limits per protocol. QTcF &gt; 450 msec.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>